Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
What is Nykode Therapeutics AS stock price today?▼
The current price of 5VB.STU is €0.26 EUR — it has increased by +3.87% in the past 24 hours. Watch Nykode Therapeutics AS stock price performance more closely on the chart.
What is Nykode Therapeutics AS stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Nykode Therapeutics AS stocks are traded under the ticker 5VB.STU.
Is Nykode Therapeutics AS stock price growing?▼
5VB.STU stock has risen by +78.32% compared to the previous week, the month change is a +4.85% rise, over the last year Nykode Therapeutics AS has showed a +80.59% increase.
When is the next Nykode Therapeutics AS earnings date?▼
Nykode Therapeutics AS is going to release the next earnings report on May 27, 2026.
How many employees does Nykode Therapeutics AS have?▼
As of April 11, 2026, the company has 59 employees.
In which sector is Nykode Therapeutics AS located?▼
Nykode Therapeutics AS operates in the Other sector.
When did Nykode Therapeutics AS complete a stock split?▼
Nykode Therapeutics AS has not had any recent stock splits.
Where is Nykode Therapeutics AS headquartered?▼
Nykode Therapeutics AS is headquartered in Oslo, Germany.